The study evaluated the efficacy and safety of lefitolimod in patients with extensive-stage small-cell lung cancer (ES-SCLC). Encouraging signals for beneficial effects on overall survival were observed in two predefined patient subgroups, although in the overall study population no relevant effect on OS could be shown.
The final study analysis included 103 patients suffering from ES-SCLC whose tumors have responded to the standard first-line chemotherapy. IMPULSE showed encouraging signals for an OS benefit in two predefined subsets of patients: (1) In patients with a low number of activated B cells, an important immune parameter (hazard ratio 0.53, 95% confidence interval 0.26-1.08). (2) In patients with reported chronic obstructive pulmonary disease, a common underlying disease for lung cancer.
Furthermore, the final analysis confirmed the favorable safety profile and the mode of action of lefitolimod.
Lefitolimod is a TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications.
Mologen AG is a biopharmaceutical company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, Mologen develops immunotherapies for the treatment of infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer